| Financier | Commitments |
|---|---|
| IDA Grant | 7.20 |
GUINEA-BISSAU COVID-19 VACCINE PROJECT
Abstract*
The proposed Project will support the Government of Guinea-Bissau efforts to further strengthen its response to COVID-19 pandemic by purchasing COVID-19 vaccines, preparing the immunization system for the deployment of the COVID-19 vaccine, and supporting the distribution of these vaccines. The proposed project will strengthen the national immunization and related health delivery system in a way that will promote an effective COVID-19 response and... Show More
Development Objective
The Project Development Objective is to prevent, detect and response to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Guinea-Bissau.
Key Details
Project Details
P176721
Closed
Opope Tshivuila Matala , Yemdaogo Tougma
Republic of Guinea Bissau
May 17, 2021
(as of board presentation)
June 29, 2021
October 20, 2021
US$ 7.20 million
Support Cell for the Management of Covid-19 Related Funds
2021
US$ 7.20 million
N/A
Substantial
June 30, 2024
No
BANK APPROVED
January 25, 2024
Finances
Financing Plan (US$ Millions)
Total Project Financing (US$ Millions)
| Product Line | IBRD/IDA |
|---|---|
| IBRD Commitment | N/A |
| IDA Commitment | 7.20 |
| IBRD + IDA Commitment | 7.20 |
| Lending Instrument | |
|---|---|
| Grant Amount | N/A |
| Total Project Cost** | 7.20 |
Summary Status of World Bank Financing (US$ Millions) as of March 31, 2025
No data available.
| Period | Financier | Transaction Type | Amount (US$) |
|---|---|---|---|
| May 16, 2024 | IDA-D9650 | Loan Cancel | 1,199,701.50 |
| Jan 18, 2023 | IDA-D8960 | Loan Disb | 11,134.90 |
| Feb 28, 2024 | IDA-D9650 | Loan Disb | 25,810.48 |
| Feb 28, 2024 | IDA-D9650 | Loan Disb | 108,061.72 |
| Dec 23, 2021 | IDA-D9650 | Loan Commitment | 2,200,000.00 |
| Jun 29, 2021 | IDA-D8960 | Loan Commitment | 5,000,000.00 |
| Mar 8, 2024 | IDA-D8960 | Loan Disb | -4,319.91 |
| Mar 8, 2024 | IDA-D8960 | Loan Disb | -340,158.94 |
| Jun 26, 2024 | IDA-D9650 | Loan Disb | 97,884.29 |
| Mar 26, 2024 | IDA-D9650 | Loan Disb | 61,077.52 |
| Jan 10, 2024 | IDA-D9650 | Loan Disb | 349,389.62 |
| Dec 12, 2023 | IDA-D8960 | Loan Disb | 46,588.07 |
| Oct 3, 2023 | IDA-D8960 | Loan Disb | 159,753.44 |
| Jul 26, 2024 | IDA-D8960 | Loan Disb | 328,827.25 |
| Jul 8, 2024 | IDA-D9650 | Loan Disb | 166,830.98 |
| Apr 3, 2024 | IDA-D8960 | Loan Disb | 410,445.90 |
| Jun 13, 2023 | IDA-D8960 | Loan Disb | 244,366.12 |
| May 19, 2023 | IDA-D8960 | Loan Disb | 953,241.30 |
| May 24, 2023 | IDA-D8960 | Loan Disb | 12,800.99 |
| Mar 13, 2023 | IDA-D8960 | Loan Disb | 236,866.06 |
| Jul 20, 2023 | IDA-D8960 | Loan Disb | 55,848.02 |
| Aug 14, 2023 | IDA-D8960 | Loan Disb | 6,603.94 |
| Sep 22, 2023 | IDA-D8960 | Loan Disb | 29,503.53 |
| Sep 7, 2023 | IDA-D8960 | Loan Disb | 670,339.70 |
| Apr 15, 2022 | IDA-D8960 | Loan Disb | 339,353.06 |
| Aug 26, 2022 | IDA-D8960 | Loan Disb | 525,000.00 |
| Sep 16, 2022 | IDA-D8960 | Loan Disb | 3,401.20 |
| Dec 14, 2022 | IDA-D8960 | Loan Disb | 22,271.50 |
| Sep 12, 2022 | IDA-D8960 | Loan Disb | 76,205.00 |
| May 3, 2023 | IDA-D8960 | Loan Disb | 278,556.72 |
| Jun 12, 2024 | IDA-D9650 | Loan Disb | 14,888.47 |
Ratings
IMPLEMENTATION RATINGS
| Name | Review | Date |
|---|---|---|
| Progress towards achievement of PDO | Moderately Satisfactory | 2023-10-16 |
| Procurement | Satisfactory | 2023-10-16 |
| Financial Management | Moderately Satisfactory | 2023-10-16 |
| Overall Implementation Progress (IP) | Moderately Satisfactory | 2023-10-16 |
| Monitoring and Evaluation | Satisfactory | 2023-10-16 |
| Project Management | Satisfactory | 2023-10-16 |
COMPLETION RATINGS
No data available.
INDEPENDENT EVALUATION RATINGS
No data available.
Results Framework
PROJECT DEVELOPMENT OBJECTIVE INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Target population fully vaccinated (by sex) Value 0.00 32.60 60.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Target population fully vaccinated (by sex) Value 0.00 32.60 60.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment By sex Value 0.00 49.09 45.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment By sex Value 0.00 49.09 45.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Population in the priority group fully vaccinated Value 0.00 23.65 20.00 Date March 1, 2021 October 11, 2023 December 31, 2022 Comment Population in the priority group fully vaccinated Value 0.00 23.65 20.00 Date March 1, 2021 October 11, 2023 December 31, 2022 Comment By sex Value 0.00 0.00 40.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment By sex Value 0.00 0.00 40.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment
INTERMEDIATE RESULTS INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Essential and frontline health workers benefitting from the first phase of vaccine deployment who are women (as percentage of the total women among essential and frontline) Value 0.00 68.93 100.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Essential and frontline health workers benefitting from the first phase of vaccine deployment who are women (as percentage of the total women among essential and frontline) Value 0.00 68.93 100.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Claims registered in the Project's grievance redress mechanism (GRM) addressed in a timely manner Value 0.00 15.00 75.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Claims registered in the Project's grievance redress mechanism (GRM) addressed in a timely manner Value 0.00 15.00 75.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment COVID-19 vaccinators trained Value 0.00 3000.00 360.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment COVID-19 vaccinators trained Value 0.00 3000.00 360.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Risk Communication and Community Engagement Strategy for COVID-19 Vaccination developed Value No Yes Yes Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Risk Communication and Community Engagement Strategy for COVID-19 Vaccination developed Value No Yes Yes Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Pharmacovigilance System (PVS) adapted to detect Adverse Events Following Vaccination (AEFI) for the COVID-19 Vaccines Value No Yes Yes Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Pharmacovigilance System (PVS) adapted to detect Adverse Events Following Vaccination (AEFI) for the COVID-19 Vaccines Value No Yes Yes Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Healthcare workers and community-based nurses trained on gender-based violence/sexual exploitation and abuse/sexual harassment Value 0.00 3000.00 300.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Healthcare workers and community-based nurses trained on gender-based violence/sexual exploitation and abuse/sexual harassment Value 0.00 3000.00 300.00 Date March 1, 2021 October 11, 2023 December 31, 2023 Comment Health centers that provide psychosocial services to GBV survivors Value 0.00 35.00 20.00 Date November 1, 2021 October 11, 2023 December 31, 2023 Comment Health centers that provide psychosocial services to GBV survivors Value 0.00 35.00 20.00 Date November 1, 2021 October 11, 2023 December 31, 2023 Comment